Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: Subgroup analysis of a randomized, controlled study

Clinical Endocrinology

Volumn 69, Issue 1, 2008, Pages 159-168

  Verbalis, Joseph G ^a,b   Zeltser, David ^c   Smith, Neila ^d   Barve, Abhijit ^d   Andoh, Masakazu ^d  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CONIVAPTAN; ELECTROLYTE; PLACEBO; POTASSIUM; SODIUM;

ANEMIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; FLUSHING; HUMAN; HYPERKALEMIA; HYPONATREMIA; HYPOTENSION; INJECTION SITE PHLEBITIS; INJECTION SITE REACTION; KIDNEY FAILURE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORTHOSTATIC HYPOTENSION; PARALLEL DESIGN; PHLEBITIS; POTASSIUM URINE LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SODIUM URINE LEVEL; THROMBOPHLEBITIS; TREATMENT RESPONSE; VITAL SIGN;

AGED; AGED, 80 AND OVER; BENZAZEPINES; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HORMONE ANTAGONISTS; HUMANS; HYPONATREMIA; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PLACEBOS; SODIUM; TREATMENT OUTCOME;

EID: 45349106231     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2007.03149.x     Document Type: Article

References (25)

1. Adrogué, H.J. Madias, N.E. (2000) Hyponatremia. New England Journal of Medicine, 342, 1581 1589.
2. Milionis, H.J., Liamis, G.L. Elisaf, M.S. (2002) The hyponatremic patient: a systematic approach to laboratory diagnosis. Canadian Medical Association Journal, 166, 1056 1062.
3. Lin, M.L., Liu, S.J. Lim, I.T. (2005) Disorders of water imbalance. Emergency Medicine Clinics of North America, 23, 749 770.
4. Upadhyay, A., Jaber, B.L. Madias, N.E. (2006) Incidence and prevalence of hyponatremia. American Journal of Medicine, 119 S30 S35.
5. Baylis, P.H. (2003) The syndrome of inappropriate antidiuretic hormone secretion. International Journal of Biochemistry and Cell Biology, 35, 1495 1499.
6. Flear, C.T., Gill, G.V. Burn, J. (1981) Hyponatraemia: mechanisms and management. Lancet, 2, 26 31.
7. Hawkins, R.C. (2003) Age and gender as risk factors for hyponatremia and hypernatremia. Clinica Chimica Acta, 337, 169 172.
8. Adrogué, H.J. (2005) Consequences of inadequate management of hyponatremia. American Journal of Nephrology, 25, 240 249.
9. Arieff, A.I., Llach, F. Massry, S.G. (1976) Neurological manifestations and morbidity of hyponatremia. correlation with brain water and electrolytes. Medicine, 55, 121 129.
10. Anderson, R.J., Chung, H.M., Kluge, R. Schrier, R.W. (1985) Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Annals of Internal Medicine, 102, 164 168.
11. Renneboog, B., Musch, W., Vandemergel, X., Manto, M.U. Decaux, G. (2006) Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. American Journal of Medicine, 119, 71. e1 71. e8.
12. 2 receptor antagonists. Journal of Molecular Endocrinology, 29, 1 9.
13. Robertson, G.L. (2001) Antidiuretic hormone. Normal and disordered function. Endocrinology and Metabolism Clinics of North America, 30, 671 694.
14. Bartter, F.C. Schwartz, W.B. (1967) The syndrome of inappropriate secretion of antidiuretic hormone. American Journal of Medicine, 42, 790 806.
15. Kraft, M.D., Btaiche, I.F., Sacks, G.S. Kudsk, K.A. (2005) Treatment of electrolyte disorders in adult patients in the intensive care unit. American Journal of Health-System Pharmacy, 62, 1663 1682.
16. Lampl, C. Yazdi, K. (2002) Central pontine myelinolysis. European Neurology, 47, 3 10.
17. 2 receptor antagonist, in vitro and in vivo. Journal of Pharmacology and Experimental Therapeutics, 282, 301 308.
18. 2 receptor antagonist, in dogs. European Journal of Pharmacology, 321, 225 230.
19. Vaprisol® (conivaptan hydrochloride injection) (2007) Prescribing information. Astellas Pharma US, Inc, Deerfield, IL.
20. 2 receptor antagonist (YM087) in the rat. European Journal of Pharmacology, 381, 23 30.
21. 2 vasopressin receptor antagonist in normal subjects. European Journal of Pharmacology, 55, 633 637.
22. Zeltser, D., Rosansky, S., van Rensburg, H., Verbalis, J.G. Smith, N Conivaptan Study Group 2007) Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. American Journal of Nephrology, 27, 447 457.
23. Lachin, J.M. (1981) Introduction to sample size determination and power analysis for clinical trials. Controlled Clinical Trials, 2, 93 113.
24. Dunnett, C.W. (1955) A multiple comparison procedure of comparing several treatments with a control. Journal of the American Statistical Association, 50, 1096 1121.
25. Dunnett, C.W. (1964) New tables for multiple comparisons with a control. Biometrics, 20, 482 491.